Chemotherapy and concomitant radiotherapy
RadiationRadiotherapy (teletherapy + high or low rate brachytherapy)
NCT Number: NCT03238261
Compare the use of radiotherapy and concomitant chemotherapy, with the single use of radiotherapy in the treatment of patients with stage IIIB uterine cancer, having as an outcome the three year survival rate, the disease free survival rate, the locoregional control of the disease and the security of the treatments provided.
Specific objectives
1. Describe and compare the demographic and clinical characteristics of both groups. 2. Compare the three year survival rate in both groups. 3. Compare the response to treatment in terms of locoregional control of the disease. 4. Compare the appearance of severe and non severe adverse events directly related to the treatment in both intervention groups.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Inclusion criteria
Women between 18 and 80 years old, diagnosed with uterine squamous cell cancer or stage IIIB adenocarcinoma (FIGO) with ECOG equal 1 or less and a Karnofsky equal or more than 70%.
Exclusion criteria
Having a concomitant or previous neoplasia, except for patients with skin tumors not associated to melanomas, platelet count under 100.000, hemoglobin levels of 10 gr/dl or above before starting the first radiotherapy session, patients with recurrent invasive uterine carcinoma, patients with compromised para aortic lymph nodes, patients with active and non controlled pelvic infection by the beginning of the treatment, creatinine depuration less than 45 ml/min confirmed with glomerular filtration rate less than 45 ml/min, neutrophils count less than 1,500/ml, and pregnant or nursing woman.
Analysis The descriptive statistical analysis will be made with proportions for the categorical variables, and for numerical variables will be made with averages, medians, standard deviations and ranges. The comparison between categorical variables will be made with square Ji proof or exact Fisher's proof when square Ji proof doesn't meet the criteria. The comparison among continuous variables with normal distribution will be established with T student distribution proof or ANOVA, and Mann-Whitnew or Kruskall proofs will be used for variables that doesn't have this type of distribution.
For the three survival rate, the Kaplan Meier method will be applied, and the survival curves will be compared with the logarithmic range proof. The Cox proportional hazard model is going to be used for the multivariate analysis and to stablish reasons. Additionally 5 interim analysis will be made.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Radiotherapy (teletherapy + high or low rate brachytherapy)
Time frame: 3 years
the disease free survival rate
Time frame: 3 years
efficacy
Time frame: 3 years
Instituto Nacional de Cancerologia, Columbia
Other Gov
CHEMOTHERAPY AND CONCOMITANT RADIOTHERAPY VS. RADIOTHERAPY IN THE TREATMENT OF PATIENTS WITH STAGE IIIB UTERINE CANCER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04557423
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04221945
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Phoenix, Arizona, United States
View Trial DetailsNCT05007106
Adenocarcinoma, Adnexal Diseases
Anchorage, Alaska, United States
View Trial DetailsNCT04694495
Communicable Diseases, DNA Virus Infections
Hefei, Anhui, China
View Trial Details